BeOne Newsroom
Media Resources
Corporate Press Kits
Review resources about BeOne, formerly BeiGene.
Product & Pipeline Media Resources
Find information about our approved medicines and pipeline molecules.
Media Library
View and download images of our leaders, facilities, company logo and other corporate assets.
Press Releases
Read our latest news.
-
August 26, 2025
BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference — SAN CARLOS, Calif.–(BUSINESS WIRE)– BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it…
-
August 25, 2025
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million — Royalty Pharma to acquire rights to BeOne’s royalties on IMDELLTRA® (tarlatamab-dlle) worldwide (ex-China) sales for up to $950 million IMDELLTRA…
-
August 21, 2025
European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications — Tablets will advance treatment simplicity and convenience to meet patient needs across Europe SAN CARLOS, Calif.–(BUSINESS WIRE)– BeOne Medicines Ltd.…
-
July 31, 2025
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia — Decision highlights the promise of BGB-16673, an investigational and potentially first-in-class BTK degrader designed to overcome resistance and deepen responses…
-
July 28, 2025
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment — Recommendation based on Phase 3 RATIONALE-315 study, in which TEVIMBRA demonstrated clinically meaningful and statistically significant improvement in event-free survival…
-
July 16, 2025
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6 — SAN CARLOS, Calif.–(BUSINESS WIRE)– BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its…
-
July 10, 2025
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma — New indication based on results of RATIONALE-309 study demonstrating statistically significant improvement in progression-free survival Second approval for TEVIMBRA in…
-
June 26, 2025
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day — BRUKINSA, sonrotoclax, and BTK CDAC data, including combinations, are designed to comprehensively address unmet needs across CLL patient populations Promising…
-
June 25, 2025
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA® — BASEL, Switzerland–(BUSINESS WIRE)– BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the…
-
June 12, 2025
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025 — Clinical results from next-generation investigational therapies demonstrate potential for deep, durable responses that support the advancement of pivotal studies and…
-
June 11, 2025
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications — New formulation provides patients with a simplified dosing experience—reducing pill burden and enhancing ease of administration—while preserving flexible dosing options…
-
June 11, 2025
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025 — SAN CARLOS, Calif.–(BUSINESS WIRE)– BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that…
Congress Hub
Review the latest information about the data we’re presenting and where you can find us.
Responsible Business & Sustainability Report
Responsible Business & Sustainability is at the core of everything we do to positively impact the lives of patients and society.
Explore More
Our Pipeline
Our broad and deep cancer pipeline is one of the largest in the industry.